Evidence map›Paper›PMID 31166942›Full record

ArticlePloS one2019

What would it cost to scale-up private sector engagement efforts for tuberculosis care? Evidence from three pilot programs in India.

Sarang Deo, Pankaj Jindal, Devesh Gupta, Sunil Khaparde, Kiran Rade, Kuldeep Singh Sachdeva, Bhavin Vadera, Daksha Shah, Kamlesh Patel, Paresh Dave and 5 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Sarang DeoIndian School of Business, Hyderabad, India.ORCID 0000-0002-3233-6014
Pankaj JindalUCLA Anderson School of Management, Los Angeles, CA, United States of America.
Devesh GuptaCentral TB Division, New Delhi, India.
Sunil KhapardeCentral TB Division, New Delhi, India.
Kiran RadeCentral TB Division, New Delhi, India.
Kuldeep Singh SachdevaCentral TB Division, New Delhi, India.
Bhavin VaderaCentral TB Division, New Delhi, India.
Daksha ShahMumbai Mission for TB Control, Mumbai, India.
Kamlesh PatelRNTCP, Gandhinagar, Gujarat, India.
Paresh DaveRNTCP, Gandhinagar, Gujarat, India.
Rishabh ChopraPATH, Connaught Place, New Delhi, India.
Nita JhaWorld Health Partners, Patna, India.
Sirisha PapineniHarvard Medical School, Boston, MA, United States of America.
Shibu VijayanPATH, Connaught Place, New Delhi, India.
Puneet DewanIndependent Consultant, Seattle, WA, United States of America.
New Delhi Tuberculosis Center · INGujarat Matikam Kalakari & Rural Technology Institute · INProgram for Appropriate Technology in Health · INAnderson University - South Carolina · USHarvard University · USIndian School of Business · INWorld Health Partners · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrivate providers dominate health care in India and provide most tuberculosis (TB) care. Yet efforts to engage private providers were viewed as unsustainably expensive. Three private provider engagement pilots were implemented in Patna, Mumbai and Mehsana in 2014 based on the recommendations in the National Strategic Plan for TB Control, 2012-17. These pilots sought to improve diagnosis and treatment of TB and increase case notifications by offering free drugs and diagnostics for patients who sought care among private providers, and monetary incentives for providers in one of the pilots. As these pilots demonstrated much higher levels of effectiveness than previously documented, we sought to understand program implementation costs and predict costs for their national scale-up. METHODS AND

findingsWe developed a common cost structure across these three pilots comprising fixed and variable cost components. We conducted a retrospective, activity-based costing analysis using programmatic data and qualitative interviews with the respective program managers. We estimated the average recurring costs per TB case at different levels of program scale for the three pilots. We used these cost estimates to calculate the budget required for a national scale up of such pilots. The average cost per privately-notified TB case for Patna, Mumbai and Mehsana was estimated to be US$95, US$110 and US$50, respectively, in May 2016 when these pilots were estimated to cover 50%, 36% and 100% of the total private TB patients, respectively. For Patna and Mumbai pilots, the average cost per case at full scale, i.e. 100% coverage of private TB patients, was projected to be US$91 and US$101, respectively. In comparison, the national TB program's budget for 2015 averages out to $150 per notified TB case. The total annual additional budget for a national scale up of these pilots was estimated to be US$267 million.

conclusionsAs India seeks to eliminate TB, extensive national engagement of private providers will be required. The cost per privately-notified TB case from these pilots is comparable to that already being spent by the public sector and to the projected cost per privately-notified TB case required to achieve national scale-up of these pilots. With additional funds expected to execute against national TB elimination commitments, the scale-up costs of these operationally viable and effective private provider engagement pilots are likely to be financially viable.

Indexed as

Cost-Benefit AnalysisDisease ManagementHumansIndiaPilot ProjectsPrivate SectorProgram EvaluationPublic SectorRetrospective StudiesTuberculosis

Identifiers

PMID31166942
PMCPMC6550378
OpenAlexW2949002199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.